Table 5.
Comparison of immunological features between anti-p200 pemphigoid with mucosal lesions and other AIBD subtypes.
| Item | Anti-p200 pemphigoid | Anti-LM332-type MMP (55) | Anti-BP180-type MMP (332) | EBA (105) | ||||
|---|---|---|---|---|---|---|---|---|
| With mucosal lesions (sole p200 Ag-M, 36) | With mucosal lesions (multiple Ags-M, 16) | With only skin lesions (sole p200 Ag-S, 82) | With only skin lesions (multiple Ags-S, 20) | |||||
| DIF | BMZ (IgG) | 23 in 24 (95.8%) | 11 in 12 (91.7%) | 17 in 17 (100.0%) | 67 in 68 (98.6%) | 55 in 55 (100.0%) | 108 in 132 (81.8%) | 80 in 83 (96.4%) |
| BMZ (IgA) | 5 in 7 (71.4%) | 1 in 5 (20.0%) | 1 in 5 (20.0%) | 9 in 12 (75.0%) | Unknown | 47 in 71 (66.2%) | 9 in 15 (60.0%) | |
| BMZ (IgM) | 0 | 1 in 4 (25.0%) | 0 | 2 in 4 (50.0%) | Unknown | 14 in 40 (35.0%) | Unknown | |
| BMZ (C3) | 23 in 24 (95.8%) | 11 in 11 (100.0%) | 17 in 17 (100.0%) | 70 in 70 (100.0%) | 41 in 55 (74.5%) | 110 in 127 (86.6%) | 72 in 75 (96.0%) | |
| IIF | BMZ (IgG) | 4 in 5 (80.0%) | 4 in 5 (80.0%) | 8 in 8 (100.0%) | 9 in 9 (100.0%) | 23 in 55 (41.8%) | 132 in 319 (41.4%) | 96 in 105 (91.4%) |
| BMZ (IgA) | 1 in 1 (100.0%) | 0 | 0 | 1 in 1 (100.0%) | Unknown | 26 in 285 (9.1%) | 3 in 48 (6.3%) | |
| ssIIF | epidermal side (IgG) | 0 | 0 | 0 | 1 in 1 (100.0%) | Unknown | 207 in 317 (65.3%) | 10 in 104 (9.6%) |
| epidermal side (IgA) | 0 | 0 | 1 in 1 (100.0%) | 1 in 1 (100.0%) | Unknown | 151 in 282 (53.55%) | 9 in 45 (20.0%) | |
| both epidermal and dermal side (IgG) | 0 | 4 in 4 (100.0%) | 11 in 11 (100.0%) | 0 | Unknown | Unknown | 10 in 104 (9.6%) | |
| both epidermal and dermal side (IgA) | 0 | 0 | 0 | 1 in 1 (100.0%) | Unknown | Unknown | 2 in 45 (4.4%) | |
| dermal side (IgG) | 26 in 27 (96.3%) | 9 in 9 (100.0%) | 7 in 7 (100.0%) | 58 in 58 (100.0%) | 48 in 55 (87.3%) | 62 in 317 (19.6%) * | 93 in 104 (89.4%) | |
| dermal side (IgA) | 4 in 5 (80.0%) | 1 in 1 (100.0%) | 0 | 2 in 3 (66.7%) | Unknown | 4 in 282 (1.42%) * | 3 in 45 (6.7%) * | |
| IB | normal human epidermal extract (IgG) | 6 in 9 (66.7%) | 0 | 1 in 2 (50.0%) | 3 in 4 (75.0%) | Unknown | Unknown | Unknown |
| normal human dermal extract (IgG) | 29 in 30 (96.7%) | 15 in 15 (100.0%) | 20 in 20 (100.0%) | 57 in 57 (100.0%) | Unknown | Unknown | 92 in 103 (89.3%) | |
| normal human dermal extract (IgA) | 1 in 1 (100.0%) | 0 | 0 | 1 in 2 (50.0%) | Unknown | Unknown | 1 in 7 (14.3%) | |
LM332, laminin 332; MMP, mucous membrane pemphigoid; EBA, epidermolysis bullosa acquisita; Ag, antigen; all 52 cases of anti-p200 pemphigoid patients with mucosal lesions were classified into 2 subgroups, (i) those with only p200 as autoantigen (sole p200 Ag-M subgroup) and (ii) those with p200 plus other autoantigens (multiple Ags-M subgroup); all 102 cases of anti-p200 pemphigoid patients with only skin lesions were also classified into 2 subgroups, (i) those with only p200 as autoantigen (sole p200 Ag-S subgroup) and (ii) those with p200 plus other autoantigens (multiple Ags-S subgroup); DIF, direct immunofluorescence; BMZ, basement membrane zone; IIF, indirect immunofluorescence; ssIIF, IIF using 1M NaCl-split skin; IB, immunoblotting; *p < 0.05 when compared with sole p200 Ag-M subgroup.